Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 4/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.37 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3405114 | 0.84 | NPC1 (0.46) | NPC1RAB9AL3MBTL1KDM4EHKDC1 | |
| SCHEMBL2866857 | 0.82 | GFER (0.39) | NPC1RAB9AL3MBTL1KDM4EHKDC1 | |
| SCHEMBL2863749 | 0.81 | NPC1 (0.40) | NPC1RAB9AL3MBTL1KDM4EHKDC1 | |
| SCHEMBL2859929 | 0.78 | ALDH1A1 (0.40) | NPC1RAB9APDE10AMEN1KMT2A | |
| SCHEMBL2861476 | 0.77 | NTRK1 (0.38) | NPC1RAB9AL3MBTL1KDM4EHKDC1 | |
| SCHEMBL2866036 | 0.75 | ALDH1A1 (0.40) | L3MBTL1PDE10AKMT2A | |
| SCHEMBL2856663 | 0.74 | PDE10A (0.33) | NPC1RAB9AL3MBTL1KDM4EHKDC1 | |
| SCHEMBL16506622 | 0.69 | PAX8 (0.48) | NPC1RAB9AL3MBTL1KDM4EHKDC1 | |
| SCHEMBL3410313 | 0.68 | NPC1 (0.46) | NPC1RAB9AL3MBTL1KDM4EHKDC1 | |
| SCHEMBL2869166 | 0.67 | EPHX2 (0.37) | NPC1RAB9AL3MBTL1KDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723366-B2 | Azole compounds as malonyl-CoA decarboxylase inhibitors for treating metabolic diseases | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-05-25 | — | — | US | disclosed |
| EP-1379243-B1 | METHODS FOR TREATING METABOLIC DISEASES USING MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2009-09-09 | — | — | EP | disclosed |
| US-20040082564-A1 | Methods for treating metabolic diseases using malonyl-coa decarboxylase inhibitors | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1379243-A1 | METHODS FOR TREATING METABOLIC DISEASES USING MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002066034-A1 | METHODS FOR TREATING METABOLIC DISEASES USING MALONYL-COA DECARBOXYLASE INHIBITORS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082564-A1 | Methods for treating metabolic diseases using malonyl-coa decarboxylase inhibitors | ME1, ME3, ME2 | NPC1 590/4885RAB9A 1607/4885L3MBTL1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.